📊 ABBV Key Takeaways
Is AbbVie Inc. (ABBV) a Good Investment?
AbbVie demonstrates strong operating profitability (26.6% operating margin, 80.4% gross margin) and solid free cash flow generation ($3.6B), but faces critical structural and growth challenges. Zero revenue growth, declining EPS, negative stockholders' equity of -$6.7B, and weak liquidity ratios (0.80 current) indicate a financially stressed company with limited strategic flexibility despite healthy core operations.
AbbVie shows strong fundamental cash generation, with $17.82B of free cash flow and a 29.1% FCF margin, which supports resilience despite modest earnings growth. However, revenue is flat, diluted EPS declined, liquidity is weak, and the balance sheet remains highly levered with negative equity, limiting the quality of the growth profile. Overall, the business is fundamentally solid but not clean enough to justify an aggressive rating based on current operating and balance-sheet trends alone.
AbbVie Inc. Key Strengths (ABBV)
- Excellent operating margin of 26.6% and gross margin of 80.4% demonstrate pricing power and operational efficiency
- Strong free cash flow generation of $3.6B with 23.8% FCF margin provides debt service capacity
- Adequate interest coverage of 5.6x provides cushion for debt obligations
- Operating cash flow of $3.8B confirms core business generates substantial cash despite balance sheet stress
- Strong free cash flow generation with $19.03B operating cash flow and $17.82B free cash flow
- Healthy operating profitability, including a 24.6% operating margin and 5.2x interest coverage
- Large-scale asset base and consistent net income generation despite sector pressures
ABBV Stock Risks: AbbVie Inc. Investment Risks
- Negative stockholders' equity of -6.7B represents severe balance sheet distress limiting strategic options
- Zero revenue growth combined with 1% net income growth signals stagnation in mature pharmaceutical business
- Liquidity crisis indicators: current ratio 0.80x and quick ratio 0.68x both below safe thresholds
- Excessive debt burden of $64.5B creates refinancing risk and constrains capital allocation
- Diluted EPS declining 1.3% YoY despite negligible revenue growth indicates deteriorating shareholder economics
- Flat revenue growth suggests limited near-term expansion and raises dependence on cost control or portfolio mix
- Negative stockholders equity and $64.50B of long-term debt indicate elevated balance-sheet risk
- Weak liquidity metrics, including a 0.67x current ratio and 0.56x quick ratio, reduce financial flexibility
Key Metrics to Watch
- Revenue growth rate - must achieve positive growth to justify current operations
- Debt reduction progress and timeline to restore positive stockholders' equity
- Free cash flow sustainability and operating cash flow maintenance under liquidity pressure
- Current and quick ratios improvement toward 1.0x+ thresholds
- EPS trajectory reversal and organic revenue growth acceleration
- Revenue growth and diluted EPS trend
- Free cash flow durability relative to debt load and liquidity
AbbVie Inc. (ABBV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
ABBV Profit Margin, ROE & Profitability Analysis
ABBV vs Healthcare Sector: How AbbVie Inc. Compares
How AbbVie Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AbbVie Inc. Stock Overvalued? ABBV Valuation Analysis 2026
Based on fundamental analysis, AbbVie Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AbbVie Inc. Balance Sheet: ABBV Debt, Cash & Liquidity
ABBV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AbbVie Inc.'s revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $2.72 reflects profitable operations.
ABBV Revenue Growth, EPS Growth & YoY Performance
ABBV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $13.3B | $695.0M | $0.39 |
| Q3 2025 | $14.5B | $186.0M | $0.10 |
| Q2 2025 | $14.5B | $938.0M | $0.52 |
| Q1 2025 | $12.3B | $1.3B | $0.72 |
| Q3 2024 | $13.9B | $1.6B | $0.88 |
| Q2 2024 | $13.9B | $1.4B | $0.77 |
| Q1 2024 | $12.2B | $239.0M | $0.13 |
| Q3 2023 | $13.9B | $1.8B | $1.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AbbVie Inc. Dividends, Buybacks & Capital Allocation
ABBV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AbbVie Inc. (CIK: 0001551152)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 12, 2026 | 8-K | tm2614276d1_8k.htm | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_050524.xml | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_050522.xml | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_050520.xml | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_050518.xml | View → |
❓ Frequently Asked Questions about ABBV
What is the AI rating for ABBV?
AbbVie Inc. (ABBV) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABBV's key strengths?
Claude: Excellent operating margin of 26.6% and gross margin of 80.4% demonstrate pricing power and operational efficiency. Strong free cash flow generation of $3.6B with 23.8% FCF margin provides debt service capacity. ChatGPT: Strong free cash flow generation with $19.03B operating cash flow and $17.82B free cash flow. Healthy operating profitability, including a 24.6% operating margin and 5.2x interest coverage.
What are the risks of investing in ABBV?
Claude: Negative stockholders' equity of -6.7B represents severe balance sheet distress limiting strategic options. Zero revenue growth combined with 1% net income growth signals stagnation in mature pharmaceutical business. ChatGPT: Flat revenue growth suggests limited near-term expansion and raises dependence on cost control or portfolio mix. Negative stockholders equity and $64.50B of long-term debt indicate elevated balance-sheet risk.
What is ABBV's revenue and growth?
AbbVie Inc. reported revenue of $15.0B.
Does ABBV pay dividends?
AbbVie Inc. pays dividends, with $3,086.0M distributed to shareholders in the trailing twelve months.
Where can I find ABBV SEC filings?
Official SEC filings for AbbVie Inc. (CIK: 0001551152) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABBV's EPS?
AbbVie Inc. has a diluted EPS of $0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ABBV's fundamental grade?
Based on our AI fundamental analysis in June 2026, AbbVie Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ABBV stock overvalued or undervalued?
Valuation metrics for ABBV: ROE of N/A (sector avg: 15%), net margin of 4.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ABBV's AI grade for 2026?
Our dual AI analysis gives AbbVie Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABBV's free cash flow?
AbbVie Inc.'s operating cash flow is $3.8B, with capital expenditures of $265.0M. FCF margin is 23.8%.
How does ABBV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.80 (avg: 2).